{"title":"ADA 2020: Ertugliflozin shown to significantly reduce heart failure hospitalization.","authors":"Iskandar Idris","doi":"10.1002/doi2.00024","DOIUrl":null,"url":null,"abstract":"<p>The SGLT2 inhibitor, Ertugliflozin was shown to be non-inferior to placebo for reducing cardiovascular events but significantly reduce heart failure hospitalization, according to a trial presented at the American Diabetes Association's 80th Conference.</p>","PeriodicalId":100370,"journal":{"name":"Diabetes, Obesity and Metabolism Now","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/doi2.00024","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity and Metabolism Now","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The SGLT2 inhibitor, Ertugliflozin was shown to be non-inferior to placebo for reducing cardiovascular events but significantly reduce heart failure hospitalization, according to a trial presented at the American Diabetes Association's 80th Conference.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
